Baker McKenzie represented H.Lundbeck A/S (Lundbeck) in the transaction, Cooley represented Longboard Pharmaceuticals and Wilson Sonsini Goodrich & Rosati represented Evercore, Longboard’s financial advisor. H. Lundbeck...
You must be a Standard 1 Year member to access this content.
Fenwick & West represented BioAge Labs, Inc. in the offering, and Cooley represented the underwriters. BioAge Labs, Inc. (Nasdaq: BIOA), a clinical-stage biopharmaceutical company developing therapeutic...
You must be a Standard 1 Year member to access this content.
Leerink Partners is serving as exclusive financial advisor to Tectonic and Cooley LLP is serving as legal counsel to Tectonic. Leerink Partners and TD Cowen are...
You must be a Standard 1 Year member to access this content.
Evercore Group L.L.C. acted as financial advisor to Merck in this transaction and Covington & Burling LLP acted as its legal advisor. Centerview Partners LLC acted...
You must be a Standard 1 Year member to access this content.
Goodwin advised Braidwell, LP on the matter. Braidwell, LP announced the consummation of an additional investment in Nevro Corp. (NYSE: NVRO), consisting of a six-year, $200,000,000 senior...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati is representing LENZ Therapeutics in the transaction, Goodwin Procter is representing Graphite Bio and Latham & Watkins is representing the placements...
You must be a Standard 1 Year member to access this content.
Goodwin advised the initial purchasers on Amphastar Pharmaceuticals, Inc.’s offering. Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced the Rule 144A offering of 2.00% Convertible Senior Notes due...
You must be a Standard 1 Year member to access this content.
Goodwin advised Scholar Rock Holding Corporation on the offering. Scholar Rock Holding Corporation (Nasdaq: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious...
You must be a Standard 1 Year member to access this content.
Goodwin advised Seagen on the deal. Nurix Therapeutics, Inc. (Nasdaq: NRIX) announced that it has entered into a multi-year, multi-target strategic collaboration agreement with Seagen Inc....
You must be a Standard 1 Year member to access this content.
